Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–49.

Article  PubMed  Google Scholar 

Pathology CSo, Center PQC, Oncology CMACSo, Cancer CA-cACSoL, Group CTO. Guidelines on clinical practice of molecular tests in non-small cell lung cancer in China. Zhonghua bing li xue za zhi = Chinese journal of pathology. 2021;50(4):323–32.

Google Scholar 

Greenhalgh J, Boland A, Bates V, et al. First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer. Cochrane Database Syst Rev. 2021;2021(3).

Rosell R, Carcereny E, Gervais R, et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol. 2012;13(3):239–46.

Article  CAS  PubMed  Google Scholar 

Zhou C, Wu Y-L, Chen G, et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. Lancet Oncol. 2011;12(8):735–42.

Article  CAS  PubMed  Google Scholar 

Shintani S, Li C, Mihara M, et al. Enhancement of tumor radioresponse by combined treatment with gefitinib (Iressa, ZD1839), an epidermal growth factor receptor tyrosine kinase inhibitor, is accompanied by inhibition of DNA damage repair and cell growth in oral cancer. Int J Cancer. 2003;107(6):1030–7.

Article  CAS  PubMed  Google Scholar 

Raben D, Bianco C, Damiano V, et al. Antitumor activity of ZD6126, a novel vascular-targeting agent, is enhanced when combined with ZD1839, an epidermal growth factor receptor tyrosine kinase inhibitor, and potentiates the effects of radiation in a human non-small cell lung cancer xenograft model. Mol Cancer Ther. 2004;3(8):977–83.

Article  CAS  PubMed  Google Scholar 

Williams KJ, Telfer BA, Stratford IJ, Wedge SR. ZD1839 ('Iressa’), a specific oral epidermal growth factor receptor-tyrosine kinase inhibitor, potentiates radiotherapy in a human colorectal cancer xenograft model. Br J Cancer. 2002;86(7):1157–61.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Zheng L, Wang Y, Xu Z, et al. Concurrent EGFR-TKI and thoracic radiotherapy as first-line treatment for stage IV non-small cell lung cancer harboring EGFR active mutations. Oncologist. 2019;24(8):1031-e1612.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Akamatsu H, Murakami H, Harada H, et al. Gefitinib with concurrent thoracic radiotherapy in unresectable locally advanced NSCLC With EGFR mutation; West Japan oncology group 6911L. J Thorac Oncol. 2021;16(10):1745–52.

Article  CAS  PubMed  Google Scholar 

Wang XS, Bai YF, Verma V, et al. Randomized trial of first-line tyrosine kinase inhibitor with or without radiotherapy for synchronous oligometastatic EGFR-mutated non-small cell lung cancer. J Natl Cancer Inst. 2023;115(6):742–8.

Article  CAS  PubMed  Google Scholar 

Peng P, Gong J, Zhang Y, et al. EGFR-TKIs plus stereotactic body radiation therapy (SBRT) for stage IV Non-small cell lung cancer (NSCLC): A prospective, multicenter, randomized, controlled phase II study. Radiother Oncol. 2023;184.

Al-Halabi H, Sayegh K, Digamurthy SR, et al. Pattern of failure analysis in metastatic EGFR-mutant lung cancer treated with tyrosine kinase inhibitors to identify candidates for consolidation stereotactic body radiation therapy. J Thorac Oncol. 2015;10(11):1601–7.

Article  CAS  PubMed  Google Scholar 

Guo T, Ni J, Yang X, et al. Pattern of recurrence analysis in metastatic EGFR-mutant NSCLC treated with osimertinib: implications for consolidative stereotactic body radiation therapy. Int J Radiat Oncol*Biol*Phys. 2020;107(1):62–71.

Shi Y, Xu H, Raynor WY, et al. Efficacy and failure patterns of early SBRT to the primary tumor in advanced EGFR-mutation-positive lung cancer with EFGR-TKI treatment: a prospective, Single Arm, Phase II study. Life. 2022;12(12).

Xu K, Liang J, Zhang T, et al. Clinical outcomes and radiation pneumonitis after concurrent EGFR-tyrosine kinase inhibitors and radiotherapy for unresectable stage III non-small cell lung cancer. Thoracic cancer. 2021;12(6):814–23.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Wang X, Zeng Z, Cai J, et al. Efficacy and acquired resistance for EGFR-TKI plus thoracic SBRT in patients with advanced EGFR-mutant non–small-cell lung cancer: a propensity-matched retrospective study. BMC Cancer. 2021;21(1).

Li Q, Hu C, Su S, et al. Impact of thoracic tumor radiotherapy on survival in non-small-cell lung cancer with malignant pleural effusion treated with targeted therapy: Propensity score matching study. Cancer Med. 2023;12(14):14949–59.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Wu J-J, Tseng J-S, Zheng Z-R, et al. Primary tumor consolidative therapy improves the outcomes of patients with advanced EGFR-mutant lung adenocarcinoma treated with first-line osimertinib. Ther Adv Med Oncol. 2024;16.

Wang X, Lu Z, Zeng Z, Cai J, Xu P, Liu A. Thoracic stereotactic body radiation therapy plus first-line tyrosine kinase inhibitors for patients with epidermal growth factor receptor-mutant polymetastatic non-small-cell lung cancer. Medicine. 2021;100(37).

Hu X, Li H, Kang X, et al. First-line tyrosine kinase inhibitors combined with local consolidative radiation therapy for elderly patients with oligometastatic non-small cell lung cancer harboring EGFR activating mutations. Front Oncol. 2022;12.

Hsu KH, Huang JW, Tseng JS, et al. Primary tumor radiotherapy during EGFR-TKI disease control improves survival of treatment Nave advanced EGFR-mutant lung adenocarcinoma patients. Onco Targets Ther. 2021;14:2139–48.

Article  PubMed  PubMed Central  Google Scholar 

Zhou F, Qin Y, Liu X, et al. Survival benefit of thoracic radiotherapy plus EGFR-TKIs in patients with non-oligometastatic advanced non-small-cell lung cancer: a single-center retrospective study. Ther Adv Med Oncol. 2023;15.

Deng R, Liu J, Song T, et al. Primary lesion radiotherapy during first-line icotinib treatment in EGFR-mutated NSCLC patients with multiple metastases and no brain metastases: a single-center retrospective study. Strahlenther Onkol. 2022;198(12):1082–93.

Article  PubMed  Google Scholar 

Sun Y, Wu M, Zhou M, et al. Management of medically inoperable and tyrosine kinase inhibitor-naïve early-stage lung adenocarcinoma with epidermal growth factor receptor mutations: a retrospective multi-institutional analysis. BMC Cancer. 2020;20(1):646.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Yen YC, Hsu HL, Chang JH, et al. Efficacy of thoracic radiotherapy in patients with stage IIIB–IV epidermal growth factor receptor-mutant lung adenocarcinomas who received and responded to tyrosine kinase inhibitor treatment. Radiother Oncol. 2018;129(1):52–60.

Article  PubMed  Google Scholar 

Scorsetti M, Franceschini D, De Rose F, et al. Stereotactic body radiation therapy: A promising chance for oligometastatic breast cancer. The Breast. 2016;26:11–7.

Article  PubMed  Google Scholar 

Su T-S. Stereotactic body radiotherapy using CyberKnife for locally advanced unresectable and metastatic pancreatic cancer. World J Gastroenterol. 2015;21(26).

Park S, Lee MH, Seong M, et al. A phase II, multicenter, two cohort study of 160 mg osimertinib in EGFR T790M-positive non-small-cell lung cancer patients with brain metastases or leptomeningeal disease who progressed on prior EGFR TKI therapy. Ann Oncol. 2020;31(10):1397–404.

Article  CAS  PubMed  Google Scholar 

Cai L, Zhu J-f, Zhang X-w, et al. A comparative analysis of EGFR mutation status in association with the efficacy of TKI in combination with WBRT/SRS/surgery plus chemotherapy in brain metastasis from non-small cell lung cancer. J Neuro-Oncol. 2014;120(2):423–430.

He Z-Y, Li M-F, Lin J-H, Lin D, Lin R-J. Comparing the efficacy of concurrent EGFR-TKI and whole-brain radiotherapy vs EGFR-TKI alone as a first-line therapy for advanced EGFR-mutated non-small-cell lung cancer with brain metastases: a retrospective cohort study. Cancer Manag Res. 2019;11:2129–38.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Wang X, Xu Y, Tang W, Liu L. Efficacy and safety of radiotherapy plus EGFR-TKIs in NSCLC patients with brain metastases: a meta-analysis of published data. Transl Oncol. 2018;11(5):1119–27.

Article  PubMed  PubMed Central  Google Scholar 

Arrieta O, Barrón F, Maldonado F, et al. Radical consolidative treatment provides a clinical benefit and long-term survival in patients with synchronous oligometastatic non-small cell lung cancer: a phase II study. Lung Cancer. 2019;130:67–75.

Article  PubMed  Google Scholar 

Geng Y, Zhang Q, Feng S, et al. Safety and Efficacy of PD-1/PD-L1 inhibitors combined with radiotherapy in patients with non-small-cell lung cancer: a systematic review and meta-analysis. Cancer Med. 2021;10(4):1222–39.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Gomez DR, Blumenschein GR, Lee JJ, et al. Local consolidative therapy versus maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer without progression after first-line systemic therapy: a multicentre, randomised, controlled, phase 2 study. Lancet Oncol. 2016;17(12):1672–82.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Li J, Wu X, Wang Z, Shen Z, Sun N, Zhu X. Ionizing Radiation Reduces TKI Resistance Caused by T790M Mutation in NSCLC Cell Lines. Zhongguo fei ai za zhi = Chinese journal of lung cancer. 2015;18(8):475–80.

PubMed  Google Scholar 

Bibby AC, Clive AO, Slade GC, et al. Survival in patients with malignant pleural effusions who developed pleural infection. Chest. 2015;148(1):235–41.

Article  PubMed  Google Scholar 

Ryu J-S, Ryu HJ, Lee S-N, et al. Prognostic impact of minimal pleural effusion in non–small-cell lung cancer. J Clin Oncol. 2014;32(9):960–7.

Article  PubMed  Google Scholar 

Iyengar P, All S, Berry MF, et al. Treatment of oligometastatic non-small cell lung cancer: an ASTRO/ESTRO clinical practice guideline. Pract Radiat Oncol. 2023;13(5):393–412.

Article